Recently, the Trump administration has reached out to GOP State Attorneys General to inform them that the Department of Health and Human Services (HHS) is reevaluating safety measures concerning mifepristone, a medication used for abortion. This communication came as Health Secretary Robert F. Kennedy Jr. and FDA Director Marty McCurry outlined in a letter—released publicly only now—that they are considering updates to risk assessment and mitigation strategies associated with the drug.
The letter indicated that the impetus for this review stems from “recent studies raising concerns about the safety of currently administered mifepristone.” However, they emphasized that HHS would undertake its own thorough investigation regarding the drug’s safety protocols. This review appears to be a response to mounting pressure from anti-abortion groups and lawmakers advocating for stricter access to mifepristone.
Originally approved by the FDA back in 2000, mifepristone has undergone various amendments over the years, including changes in 2016 and 2021 that expanded the gestational limit for use to up to ten weeks and allowed for more accessible prescriptions via telehealth. Current FDA guidelines assert that mifepristone is safe and effective as part of a drug abortion regimen, alongside misoprostol.
Nevertheless, anti-abortion advocates argue that the drug poses significant risks. Some concerns raised in recent studies, particularly from conservative think tanks, suggest that protective measures overseeing the use of mifepristone have been notably weakened, and it remains uncertain whether Kennedy and McCurry will recommend pulling the drug from the market entirely.
Overall, the ongoing discourse around mifepristone is indicative of the larger battles over reproductive rights and public health policy—tensions that are sure to continue as new studies and reviews emerge.
